Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials
Rosen E, Schonhoft J, Silverman I, Yablonovitch A, Sethuraman S, Nejad P, Ulanet D, Yang J, Kim I, Fei K, Xu Y, Lagow E, Zhang S, Cai M, Koehler M, Carneiro B, Lheureux S, Cecchini M, Herzberg B, Reis-Filho J, Rimkunas V, Yap T. Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials. Molecular Cancer Therapeutics 2023, 22: a123-a123. DOI: 10.1158/1535-7163.targ-23-a123.Peer-Reviewed Original ResearchCirculating tumor DNAVariant allele frequencyDNA damage repairEpigenomic profilingTumor DNADamage repairResponse monitoringCirculating tumor DNA sequencingLow variant allele frequencyTreated with PARPiPhase 1 studyCell-free DNAMolecular responseIntragenic deletionsEpigenetic analysisAllele frequenciesRad3-relatedCH variantsGenomic alterationsOn-treatmentClinical outcomesPancreatic cancerAtaxia telangiectasiaPathogenic alterationsEvaluable ptsPerformance of Circulating Tumor DNA (ctDNA) Genomic and Epigenomic Profiling (GuardantINFINITY) in the TRESR and ATTACC Studies
Silverman I, Schonhoft J, Yablonovitch A, Lagow E, Cecchini M, Herzberg B, Reis-Filho J, Rosen E, Rimkunas V, Yap T. Performance of Circulating Tumor DNA (ctDNA) Genomic and Epigenomic Profiling (GuardantINFINITY) in the TRESR and ATTACC Studies. The Journal Of Liquid Biopsy 2023, 1: 100014. DOI: 10.1016/j.jlb.2023.100014.Peer-Reviewed Original ResearchTumor DNAEpigenomic profiling